{"id":452310,"date":"2021-03-08T06:53:12","date_gmt":"2021-03-08T11:53:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452310"},"modified":"2021-03-08T06:53:12","modified_gmt":"2021-03-08T11:53:12","slug":"novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/","title":{"rendered":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference"},"content":{"rendered":"

<\/p>\n

NovaBay Pharmaceuticals to Participate in Virtual 33rd<\/sup> Annual Roth Conference<\/b><\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE<\/a>)–
\nNovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae <\/sup>for the eye care market and CelleRx\u00ae<\/sup> Clinical Reset\u2122 for the beauty market, announces that management will hold one-on-one investor meetings at the Virtual 33rd<\/sup> Annual Roth Conference being held March 15-17, 2021.\n<\/p>\n

\nInvestors interested in arranging a meeting with NovaBay management should contact their Roth Capital Partners sales representative or LHA Investor Relations. The NovaBay corporate presentation can be access from the Investors section of the Company\u2019s website here<\/a>. Roth Conference information is available here<\/a>.\n<\/p>\n

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics\u00ae<\/sup><\/b><\/p>\n

\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX\u00ae<\/sup> family of products and the AGANOCIDE\u00ae<\/sup> compounds. The Neutrox family of products includes AVENOVA\u00ae<\/sup> for the eye care market, NEUTROPHASE\u00ae<\/sup> for wound care market, and CELLERX\u00ae<\/sup> for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.\n<\/p>\n

Socialize and Stay informed on NovaBay\u2019s progress
\n
<\/span><\/b>Like us on Facebook
\n<\/a>
Follow us on Twitter
\n<\/a>
Connect with NovaBay on LinkedIn
\n<\/a>
Visit NovaBay\u2019s Website<\/a><\/p>\n

Avenova Purchasing Information
\n
<\/span><\/b>For NovaBay Avenova purchasing information:
\n
Please call 800-890-0329 or email sales@avenova.com
\n<\/a>
Avenova.com<\/a><\/p>\n

CelleRx Clinical Reset Purchasing Information
\n
<\/span><\/b>For NovaBay CelleRx Clinical Reset purchasing information
\n
Please call 877-CELLERX
\n
www.CelleRx.com<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210308005092\/en\/<\/a><\/span><\/p>\n

NovaBay Contact
\n<\/span><\/b>
Justin Hall
\n
Chief Executive Officer and General Counsel
\n
510-899-8800
\n
jhall@novabay.com<\/a><\/p>\n

Investor Contact
\n<\/span><\/b>
LHA Investor Relations
\n
Jody Cain
\n
310-691-7100
\n
jcain@lhai.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health FDA Other Health Clinical Trials Pharmaceutical Optical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference EMERYVILLE, Calif.–(BUSINESS WIRE)– NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae for the eye care market and CelleRx\u00ae Clinical Reset\u2122 for the beauty market, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. Investors interested in arranging a meeting with NovaBay management should contact their Roth Capital Partners sales representative or LHA Investor Relations. The NovaBay corporate presentation can be access from the Investors section of the Company\u2019s website here. Roth Conference information is available here. About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics\u00ae NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing … <\/p>\n

Continue reading “NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-452310","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference EMERYVILLE, Calif.–(BUSINESS WIRE)– NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae for the eye care market and CelleRx\u00ae Clinical Reset\u2122 for the beauty market, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. Investors interested in arranging a meeting with NovaBay management should contact their Roth Capital Partners sales representative or LHA Investor Relations. The NovaBay corporate presentation can be access from the Investors section of the Company\u2019s website here. Roth Conference information is available here. About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics\u00ae NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing … Continue reading "NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-08T11:53:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference\",\"datePublished\":\"2021-03-08T11:53:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/\",\"name\":\"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-08T11:53:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference - Market Newsdesk","og_description":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference EMERYVILLE, Calif.–(BUSINESS WIRE)– NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae for the eye care market and CelleRx\u00ae Clinical Reset\u2122 for the beauty market, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. Investors interested in arranging a meeting with NovaBay management should contact their Roth Capital Partners sales representative or LHA Investor Relations. The NovaBay corporate presentation can be access from the Investors section of the Company\u2019s website here. Roth Conference information is available here. About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics\u00ae NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing … Continue reading \"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-08T11:53:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference","datePublished":"2021-03-08T11:53:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/"},"wordCount":323,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/","name":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-08T11:53:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210308005092r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-virtual-33rd-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NovaBay Pharmaceuticals to Participate in Virtual 33rd Annual Roth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=452310"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/452310\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=452310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=452310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=452310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}